Welcome to our dedicated page for Dentsply Sirona SEC filings (Ticker: XRAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DENTSPLY SIRONA Inc. (Nasdaq: XRAY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, which the company uses to announce material events such as quarterly financial results, leadership changes, strategic reviews and key governance decisions.
In its Form 8-K filings, Dentsply Sirona reports results of operations and financial condition for recent quarters, including segment and geographic performance, non-GAAP metrics and information about goodwill and intangible asset impairments. The company also files 8-Ks to disclose changes in executive officers, retention equity incentive awards, formation of board-level committees and updates on matters such as the conclusion of an SEC Division of Enforcement investigation without enforcement action.
Other filings referenced by the company, such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, contain detailed risk factors, financial statements and management discussion that are incorporated by reference in forward-looking statements. These documents provide context on how Dentsply Sirona views risks related to its dental products, technologies, segments and global operations.
On Stock Titan, investors can review these filings alongside AI-powered summaries that explain the significance of each document in straightforward language. Real-time updates from EDGAR help users follow new 8-Ks reporting quarterly earnings, leadership transitions or strategic portfolio decisions, as well as periodic reports like 10-K and 10-Q when available. For those monitoring governance and incentives, filings also describe compensation arrangements, retention grants and board committee structures. This page is a focused resource for understanding how Dentsply Sirona communicates material information, manages regulatory obligations and frames risks and opportunities in its official SEC documents.
DENTSPLY SIRONA Inc. executive Aldo Mariano Roberto Denti, EVP and Chief Commercial Officer, reported receiving new equity awards. On March 4, 2026, he was granted stock options for 270,200 shares and 59,524 shares of common stock through restricted stock units. Both the RSUs and options vest in one-third annual installments over three years, ending March 4, 2029. The options have an exercise price set at 110% of the company’s closing common stock price on the grant date, aligning the award’s value with future share performance.
DENTSPLY SIRONA Inc. President and CEO Daniel T. Scavilla reported equity compensation awards. He received stock options covering 2,066,600 shares, which vest in annual one-third increments over three years ending March 4, 2029, with an exercise price equal to 115% of the closing price on the grant date.
He also received 145,089 shares of common stock in the form of Restricted Stock Units, vesting one-third annually over the same three-year period ending March 4, 2029. Following these awards, his directly owned common stock holdings increased to 161,839.066 shares, and he directly holds 2,066,600 stock options.
DENTSPLY SIRONA Inc. senior vice president Robert Anthony Johnson reported equity awards that increase his direct ownership stake. On March 4, 2026, he was granted stock options for 202,700 rights to buy shares and an award of 44,643 shares of common stock.
The common stock award consists entirely of restricted stock units that vest in one-third annual installments over three years, ending March 4, 2029
DENTSPLY SIRONA Inc. granted stock options to senior executive Robert Anthony Johnson, who serves as SVP and Chief Supply Chain Officer. The award covers 471,400 stock options, recorded as a direct beneficial holding after the transaction.
According to the terms, these options will cliff-vest on the third anniversary of the grant date, meaning none are exercisable until that date. The exercise price will be set at 110% of the closing price of DENTSPLY SIRONA common stock on the grant date, aligning the award’s value with future share performance.
DENTSPLY SIRONA Inc. senior vice president and Chief Supply Chain Officer Robert Anthony Johnson reported share dispositions that were made to cover tax obligations, not open-market sales. On March 4, 2026, 1,026 common shares were withheld at $13.44 per share, leaving 117,176.146 shares held directly.
On March 3, 2026, two similar tax-withholding transactions occurred, with 3,229 and 4,481 common shares withheld at $13.30 per share. Footnotes explain these shares were retained by the company to satisfy taxes due upon vesting of previously granted restricted and performance-based stock units.
DENTSPLY SIRONA Inc. senior vice president and chief human resources officer Andrea L. Frohning reported tax-related share dispositions tied to vesting equity awards. On March 3 and 4, 2026, a total of 5,657 shares of common stock were withheld to cover tax liabilities at prices between $13.30 and $13.44 per share. These are coded as tax-withholding dispositions, not open-market sales. After the most recent withholding, Frohning directly holds 37,206.252 shares of DENTSPLY SIRONA common stock.
DENTSPLY SIRONA Inc. reported that officer Kevin Czerney, its VP and Chief Accounting Officer, had company shares withheld to cover tax obligations from vesting equity awards. On March 3, 2026, tax-withholding dispositions of 527 and 1,197 shares of common stock occurred at prices of $13.30 per share. On March 4, 2026, an additional 328 shares were withheld at $13.44 per share. These transactions relate to the vesting of performance-based and time-based restricted stock units and associated dividend equivalent units and are not open-market sales.
DENTSPLY SIRONA Inc. director Gregory T. Lucier reported indirect open-market purchases of the company’s common stock through a trust. On March 2 and 3, the trust bought a total of 50,000 shares at weighted average prices of $14.245 and $14.028 per share.
The trust now holds 50,000 shares, while additional indirect holdings shown include 24,901.284 shares through a family partnership and 21,000 shares in a Gregory Lucier IRA. The filing notes the trust is one where Lucier serves as trustee and beneficiary and that he disclaims beneficial ownership beyond his pecuniary interest.
Johnson Robert Anthony reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. senior vice president Robert Anthony Johnson reported an award of 9,599 shares of common stock at no cost, increasing his directly held stake to 125,912.146 shares. The filing also notes that performance criteria for 1,478 performance-based restricted stock units granted on March 3, 2023 were certified as attained on March 2, 2026, with those units scheduled to vest into common shares on March 3, 2026.
DENTSPLY SIRONA Inc. reported that executive Andrea L. Frohning, SVP and CHRO, acquired 8,861 shares of common stock as a stock award. The shares were received at no cash cost per share, increasing her directly held position to 42,863.252 shares.
According to a footnote, this relates to performance-based restricted stock units granted on March 3, 2023. The issuer’s Compensation Committee certified that the performance criteria were met and 1,478 PRSUs were attained on March 2, 2026, with those PRSUs scheduled to vest into shares on March 3, 2026.